Amneal Pharmaceuticals Expands Manufacturing Presence in India with New Facilitie
Amneal to invest up to $200 million for advanced peptide synthesis and sterile fill-finish facilities in Ahmedabad
- By Newsdesk
- New Delhi
- Oct 08, 2024
Amneal Pharmaceuticals, a global pharmaceutical company headquartered in the United States, has unveiled plans to establish two new manufacturing plants in Ahmedabad, India. This development highlights the company's ongoing expansion in India, where it has been operational since 2008. The investment, estimated at between $150 million and $200 million, will be rolled out over the next four to five years. The facilities will focus on advanced peptide synthesis and sterile fill-finish manufacturing.
Established in 2002 by Chirag and Chintu Patel in New Jersey, Amneal Pharmaceuticals has built a significant global presence, with manufacturing sites in the U.S., India, and Ireland. In India, the company already operates eight facilities across key locations such as Ahmedabad, Dahej, Hyderabad, and Vizag, supported by commercial offices in Mumbai. Amneal’s product portfolio comprises over 280 products across various categories, including retail pharmaceuticals, injectables, biosimilars, and specialty medicines. These products are driven by the company’s global research and development capabilities.
This new investment will further enhance Amneal’s ability to produce next-generation treatments, particularly for metabolic diseases and obesity. The focus will include the development of GLP-1 and amylin receptor agonists in partnership with Metsera. These upcoming facilities will integrate seamlessly with the company’s existing infrastructure and strengthen its capacity for innovation.
Commenting on the development, co-founders and co-CEOs Chirag and Chintu Patel said, “Amneal has evolved into one of the most trusted pharmaceutical companies globally, with a strong foundation in research and development, production, and commercial infrastructure. These new facilities reflect our commitment to advancing the development and manufacturing of cutting-edge medicines at scale in India for both the local and global markets.”
Amneal’s investments in India have totaled approximately $600 million over the past decade, covering capital projects, acquisitions, and R&D efforts. The company’s current Indian facilities produce around 60 million units of injectables and 8.5 billion tablets each year. These include dedicated operations for injectables, active pharmaceutical ingredients, and oral solid dosage products.
Employing more than 5,500 professionals in India, Amneal's workforce spans research, regulatory, manufacturing, and supply chain roles. The new facilities are expected to generate further employment opportunities in advanced manufacturing and R&D, reinforcing the company’s operations in the country. Emphasizing the importance of its workforce, the company stated, “People are the heart of everything Amneal does, and our team members are like family.”
Amneal has also expanded its pharmaceutical portfolio in India in recent years, introducing products in areas such as hospital critical care, ophthalmology, diagnostics, neurology, rare diseases, oncology, and specialty treatments. With its ongoing collaboration with Metsera, the company aims to deliver innovative solutions for metabolic diseases and obesity to the Indian market, further solidifying its commitment to providing high-quality, accessible medicines in the region.